Top

News & Events

Archive: 2019

News Archive

Lifestars Awards 2019

19 November 2019
Lifestars Awards 2019
London, UK

Read more »

OBN Awards 2019

07 November 2019
OBN Awards 2019
Oxford, UK

Read more »

OBN BioForward 2019

11 October 2019
OBN BioForward 2019
Birmingham, UK

Read more »

BIA UK CEO and Investor Forum 2019

24-25 June 2019
BIA UK CEO and Investor Forum 2019
Chesham, UK

Read more »

European Mediscience Awards 2019

13 June 2019
European Mediscience Awards 2019
London, UK

Read more »

Ernst & Young IPO Retreat 2019

20-21 May 2019
Ernst & Young IPO Retreat 2019
Surrey, UK 

Read more »

14th Annual World Advanced Therapies & Regenerative Medicine Congress

15 - 17 May 2019
14th Annual World Advanced Therapies & Regenerative Medicine Congress
London, UK

Read more »

OBN BioTrinity 2019

30 April - 1 May 2019
OBN BioTrinity 2019
London, UK

Read more »

Cell & Gene Meeting on the Mediterranean

23 - 25 April 2019
Cell & Gene Meeting on the Mediterranean
Barcelona, Spain

Read more »

Friends of Edison Spring Drinks

28 March 2019
Friends of Edison Spring Drinks
London, UK

Read more »

Labiotech - Refresh #13 in Vienna

27 March 2019
Labiotech - Refresh #13 in Vienna
Vienna, Austria

 

Read more »

National Care Group expands in Gloucester by completing acquisition of Branksome House Care Services

Accrington, UK – National Care Group (“NCG”), a leading provider of support services, announces the acquisition of the business and assets of Branksome House Care Services (“Branksome”), through its subsidiary Chosen Care Limited. Financial details of the deal were not disclosed.

Read more »

Imugene’s Pre-IND FDA Meeting Provides Guidance for KEY-Vaxx Immunotherapy Clinical Development Plan

Sydney, Australia – Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced it had received and accepted the minutes of its Pre-Investigational New Drug (IND) meeting with the US Food and Drug Administration (FDA) for its KEY-Vaxx cancer immunotherapy on 8 February 2019.

Read more »

ART MEDICAL: New Technologies Needed to Address Inadequate Implementation of Nutritional Guidelines Across the Majority of Intensive Care Units

Tel Aviv, Israel – ART MEDICAL, a medical device company that specializes in nutrition-based intensive care unit (ICU) technology, today announced the publication of an article that outlines the limitations of current ICU nutrition methods and provides insights into cutting-edge technologies that may advance this critical component of patient care into the 21st Century.  Pierre Singer, Professor of Anesthesia and Intensive Care, Sackler School of Medicine, Tel Aviv University, and ART MEDICAL CEO, Liron Elia, co-authored the article, which appears in the current issue of ICU Management & Practice Journal.

Read more »

China National Biotec Group (CNBG) and ImmunoBiology Ltd enter licensing agreement to co-develop next generation vaccine against pneumococcal disease in Greater China

Cambridge, UK - ImmunoBiology Ltd (ImmBio), a vaccine R&D company based at Babraham Research Campus near Cambridge UK, has recently signed a licensing agreement with LIBP (Lanzhou Institute of Biological Product) a subsidiary company under CNBG.

Read more »

USA Patent Granted for Recce's Antibiotics

Sydney, Australia – Recce Pharmaceuticals Ltd (ASX:RCE) (Recce or the Company), the Company developing a new class of broad spectrum synthetic antibiotics, today announced the US Patents and Trademarks Office had Granted 23 claims for patent US 10,226,482 B2, ‘Copolymer and Method for Treatment of Bacterial Infection’.

Read more »

Imugene Announces First Patient Dosed in the Open-Label Phase 2 Study with HER-Vaxx Cancer Vaccine for Advanced Gastric Cancer

SYDNEY, Australia – Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced dosing of the first patient in an open-label, randomised multi-centre Phase 2 study with its HER-Vaxx (IMU-131) cancer vaccine for the treatment of HER-2 positive gastric cancer patients.

Read more »

BIA Women in Biotech Networking Evening - March

7 March 2019
BIA Women in Biotech Networking Evening - March
London, UK

Read more »

Women in Business Lunch

05 March 2019
Women in Business Lunch
London, UK

Read more »

Health for Life Capital II™, World Leading Microbiome-focused Fund Announces its First Close

Paris, France – Seventure Partners, one of Europe’s leaders in financing innovation and a world-leader in life science microbiome investment, announces it has completed the first closing of its second dedicated fund focused on the microbiome, and health, nutrition and digital/connected health sectors, Health for Life Capital II™ (HFL II), with a target for the final close of over €200 million.

Read more »

Clinigen and Eiger BioPharmaceuticals launch worldwide Managed Access Program for lonafarnib for patients with Progeria and Progeroid Laminopathies

Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, has partnered with Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR, ‘Eiger’) to launch a worldwide lonafarnib Managed Access Program for patients with Progeria and Progeroid Laminopathies.

Read more »

Xellia Pharmaceuticals Divests Raleigh, North Carolina Production Facilities to Sagent Pharmaceuticals

Copenhagen, Denmark – Xellia Pharmaceuticals (‘Xellia’), a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections has entered into an agreement to divest Xellia’s Raleigh, North Carolina manufacturing plant to Sagent Pharmaceuticals Inc., (‘Sagent’), a leader of specialty pharmaceutical products with an emphasis on the injectable market.

Read more »

Seventure Partners Life Sciences Corporate Update September 2018 – February 2019

Paris, France – Seventure Partners (Seventure), one of Europe’s leaders in financing innovation and a world-leader in the venture investment in the microbiome sector, is pleased to provide an update on its life science investments for the period September 2018 to February 2019.
 

Read more »

Confo Therapeutics forms Scientific Advisory Board as it accelerates development of proprietary drug discovery engine

Ghent, Belgium – Confo Therapeutics, an emerging drug discovery company, today announces the formation of its Scientific Advisory Board (SAB) with four key appointments: Radu Aricescu, Peter Kolb, Graeme Milligan and Jan Steyaert, Founder of Confo Therapeutics, who will serve as Chairman of the SAB.

Read more »

Clinigen half year results - Good H1 performance with adjusted EPS up 9% and strong cash flow

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or ‘the Group’), the global pharmaceuticals and services group, has today published its half year results for the six months ended 31 December 2018.

Read more »

Dr. Athanasios Papadopoulos joins Emergex as Chief Medical Officer

Oxford, UK – Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to synthetic vaccine development in the field of infectious diseases, today announces the appointment of Athanasios Papadopoulos, MD, as Chief Medical Officer (CMO), effective 1st March 2019. Dr. Papadopoulos will report directly to Emergex’s CEO Professor Thomas Rademacher.

Read more »

Abcam moves to new purpose-built global headquarters

Cambridge, UK - Abcam, a global innovator in life science reagents and tools, is pleased to announce its move to new state-of-the-art global headquarters, Discovery Drive, on the Cambridge Biomedical Campus (CBC), UK, a leading hub of healthcare, science and medical research.

Read more »

Cell Medica Awarded USD 8.7 Million CPRIT Grant to Accelerate CMD-502 Off-the-shelf CAR-NKT Cell Therapy into Clinical Development

HOUSTON and LONDON – Cell Medica announced today that it has been awarded an $8.7 million research grant from the Cancer Prevention and Research Institute of Texas (CPRIT). The grant will support preclinical and clinical development of the company’s off-the-shelf chimeric antigen receptor-natural killer T cell (CAR-NKT) therapies to treat hematological and solid tumors.

Read more »

Immatics Announces Clinical Trial Collaboration in Immunotherapy for Solid Cancers

Houston, Texas and Tuebingen, Germany – Immatics today announced a collaboration with Roche to evaluate the safety and efficacy of IMA101, Immatics’ investigational autologous cell therapy, in combination with atezolizumab (TECENTRIQ®), in patients with solid cancers.

Read more »

HOOKIPA Pharma Raises $37.4 million (€33.2 million) in Series D Financing

New York, US and Vienna, Austria – HOOKIPA Pharma Inc. (“HOOKIPA”), a company developing a new class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that it has completed a $37.4 million (€33.2 million) series D financing.

Read more »

Sachs Associates 12th​ Annual European Life Sciences CEO Forum

25-26 February 2019
Sachs Associates 12th Annual European Life Sciences CEO Forum
Zurich, Switzerland

Read more »

Clinigen granted additional indication for Glycopyrronium Bromide to treat paediatric and adolescent severe hypersalivation

Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, has been granted by the Medicines and Healthcare products Regulatory Agency (MHRA), an additional indication for Glycopyrronium Bromide 1mg/5ml Oral Solution (‘Glyco’). The new indication covers the use of Glyco in children and adolescents aged three years and older with chronic neurological disorders as symptomatic treatment of hypersalivation (severe sialorrhoea).

Read more »

Seventure Keeps up Pace of Its International Microbiome Investments, Closing Four Deals Spanning Seed to Series C

Paris, France – Seventure Partners, one of Europe’s leaders in financing innovation and a world-leader in life science microbiome investment, has closed four new investments across four countries over the past few months. The investments span the spectrum of venture investing, from seed to series C.

Read more »

Xellia Pharmaceuticals Receives US FDA Approval for Premixed Vancomycin Injection

Copenhagen, Denmark and Buffalo Grove, IL, USA - Xellia Pharmaceuticals (‘Xellia’), a global leader in the manufacturing of specialty anti-infective treatments, announced today it has received U.S. Food and Drug Administration (FDA) approval for Premixed Vancomycin Injection in a Ready-to-Use (RTU) bag in the United States market. This approval follows Qualified Infectious Disease Product (QIDP) designation from the FDA in February 2018.

Read more »

SkinBioTherapeutics plc - Issue of Equity and Related Party Transaction

Manchester, UK – SkinBioTherapeutics plc (AIM: SBTX) (“SkinBioTherapeutics” or the “Company”), a life sciences company focused on skin health, announces that it has raised a total of £1,500,000 via a placing of 9,375,000 new ordinary shares (“Placing Shares”) at a price of 16 pence per share (the “Placing”).

Read more »

Recce Successfully Raises AUD$1.8 million to Advance Lead Antibiotic Program

Sydney, Australia – Recce Pharmaceuticals Ltd (ASX: RCE) (Recce or the Company), is pleased to announce that it has raised approximately AUD$1.8m (before costs) from sophisticated and institutional investors that will result in 12,857,143 fully paid ordinary shares being issued at AUD$0.14 per share (Placement).

Read more »

Emergex Secures State-of-the-art R&D Facility and Hires a Chief Scientific Officer to Drive Development of its Vaccines

Oxford, UK – Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a novel approach to the development of vaccines for infectious diseases, today announces that it has successfully secured a state-of-the-art research and development (R&D) facility at Milton Park, Oxfordshire.

Read more »

HOOKIPA Appoints Michael A. Kelly as Independent Director

New York, US and Vienna, Austria – HOOKIPA Pharma Inc. (“HOOKIPA”), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced the appointment of Michael A. Kelly to the Company’s Board of Directors.

Read more »

BIA Committee Summit 2019

14 February 2019
BIA Committee Summit 2019
London, UK

Read more »

Feedback Medical appoints radiologist and NHS England Clinical Entrepreneur Fellow as CEO

Cambridge, UK - Feedback plc (AIM: FDBK, "Feedback", or the “Company”), the specialist medical imaging technology company, announces that its operating subsidiary, Feedback Medical Ltd, has appointed Dr Tom Oakley as its Chief Executive Officer.

Read more »

SkinBioTherapeutics Half Year Results

Manchester, UK – SkinBioTherapeutics plc (AIM: SBTX or the “Company”) a life sciences company focused on skin health, has announced its half year results for the six months to 31 December 2018.

Read more »

OBN BioTuesday: 'What's New in Microbiome Research'

12 February 2019
OBN BioTuesday: 'What's New in Microbiome Research'
Cambridge, UK

Read more »

SAW Diagnostics Receives £1.5M Innovate UK Funding to Support Commercialisation of its Point-of-Care Diagnostics Technology Platform

Glasgow, Scotland – SAW Diagnostics Limited (SAW Dx), an emerging biological sample analysis and point-of-care diagnostic company, announced today that Innovate UK, the UK’s innovation Agency, has awarded the company a £1.5M grant in support of the company’s low-cost sample preparation system, for use in infectious disease detection and other applications.

Read more »

Biotec Pharmacon’s subsidiary, ArcticZymes launches its first ligase enzyme

Tromsø, Norway - Biotec Pharmacon's (OSE: Biotec) subsidiary ArcticZymes adds its first ligase enzyme, T4 DNA ligase, to its portfolio. T4 DNA ligase, the most widely used enzyme in the ligase family, works by joining DNA fragments together. It is used in the development of kits and products serving the In Vitro Diagnostic (IVD) and molecular research market segments.

Read more »

BioWednesday London: The J P Morgan Healthcare Conference: The Mood Music

06 February 2019
BioWednesday London: The J P Morgan Healthcare Conference: The Mood Music
Instinctif Office, London, UK

Read more »

Nick Keher appointed CFO of Clinigen Group

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, has appointed Nick Keher Group Chief Financial Officer with effect from 19 March 2019. He will replace Martin Abell, who has resigned and leaves the business on 31 March 2019.

Read more »

Biotec Pharmacon awarded grant from Research Council of Norway to develop next-generation wound product

Tromsø, Norway – Biotec Pharmacon (OSE: Biotec) announces today that its subsidiary Biotec BetaGlucans has been awarded up to NOK 8 million in a grant by the Research Council of Norway for a project titled “Bioactive wound healing dressing with beta-glucan for treatment of hard-to-heal wounds”. The project is to be supported over 4 years.

Read more »

Interim update on human studies and extension of IP portfolio

Manchester, UK – SkinBioTherapeutics plc (AIM: SBTX – “SkinBioTherapeutics” or the “Company”), a life science company focused on skin health, provides interim data on the third and final phase of its human studies and an update on one of its patents.

Read more »

Biotec Pharmacon Q4 2018 Results

Biotec Pharmacon (OSE: Biotec) announces its Q4 2018 results and full year 2018 results to 31 December 2018.

Read more »

Biotec Pharmacon finalises Post Market study on Woulgan®

Tromsø, Norway – Biotec Pharmacon's (OSE: Biotec) has announced that its subsidiary, Biotec BetaGlucans, has finalised treatment in a UK Post Market Clinical Follow-up (PMCF) study on its wound care gel, Woulgan®, in diabetic foot ulcer patients.

Read more »

Abcam expands custom services capabilities with the acquisition of Calico Biolabs

Cambridge, UK - Abcam, a global innovator in life science reagents and tools, is pleased to announce its acquisition of Calico Biolabs, a developer of custom high-quality recombinant rabbit monoclonal antibodies for diagnostics and pharmaceutical company partners.

Read more »

Microbiotica Presenting at Key Microbiome Events in Q1 2019

Cambridge, UK - Microbiotica, a leading player in microbiome-based therapeutics, is pleased to confirm upcoming conference activity for the first quarter of 2019.

Read more »

ERA Consulting: The Journey of Biopharmaceutical Innovation

25 January 2019
ERA Consulting: The Journey of Biopharmaceutical Innovation
London, UK

Read more »

BIA Gala Dinner 2019

24 January 2019
BIA Gala Dinner 2019
London, UK

Read more »

BIA Strategic Technologies in Life Sciences: The Future is now

24 January 2019
BIA Strategic Technologies in Life Sciences: The Future is now
London, UK

Read more »

Feedback plc Half Year Result

Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, announces its unaudited half year results for the six months to 30 November 2018.

Read more »

New Combined Diagnostic and Antimicrobial Susceptibility Test Enables Resistance-Guided Therapy for Gonorrhoea

SYDNEY, AUSTRALIA and LONDON, UK – UK patients with N. gonorrhoeae (GC) now have the option of receiving the cheap and easily-administered oral antibiotic ciprofloxacin thanks to updated treatment guidelines and the availability of a novel molecular diagnostic and antimicrobial susceptibility test (AST). The new test can simultaneously diagnose gonorrhoea and provide information on whether a patient will respond to ciprofloxacin.1

Read more »

Abcam and the Loulou Foundation partner to develop key research tools for CDKL5 deficiency disorder

London and Cambridge, UK - Today, Abcam, a global innovator in life science reagents and tools, and the Loulou Foundation, a private UK-based foundation dedicated to the development of therapeutics for CDKL5 Deficiency Disorder, announced a research collaboration to discover new tools to advance research in this area of high unmet medical need.

Read more »

Autifony Therapeutics achieves first milestone in agreement with Boehringer Ingelheim for a novel therapeutic approach to a range of CNS disorders

Stevenage, UK – Autifony Therapeutics Limited (“Autifony”), a clinical stage company developing new drugs to treat serious disorders of the nervous system, today announced that the first milestone has successfully been achieved under Autifony’s option agreement with Boehringer Ingelheim. As announced previously, Boehringer Ingelheim acquired an exclusive option to purchase Autifony’s Kv3.1/3.2 positive modulator platform in December 2017. Further details of the milestone were not disclosed.

Read more »

Clinigen Half Year trading update

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, today provides an unaudited trading update for the six months ended 31 December 2018.

Read more »

Clinigen extends exclusive European clinical trial sourcing and supply agreement with Accord Healthcare

Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, announces that its Clinical Trial Service (‘CTS’) business has extended its exclusive European clinical trial supply agreement with Accord Healthcare (‘Accord’). Clinigen is also offering pharma companies an ‘on demand’ service to Accord’s products, a first for the industry.

Read more »

Instinctif Partners’ Life Science Practice Joins New Integrated Group of Specialist Life Science Advisors, Launched at JP Morgan 2019

London, UK – The Life Science Practice of Instinctif Partners, the business communications consultancy, is pleased to announce that it has joined with other sector specialist advisors in a new integrated healthcare solution, to be formally launched by the Bridgehead Group during the annual JP Morgan conference in San Francisco from 7-9 January 2019.

Read more »

Crescendo Biologics announces Humabody® evaluation in CAR-T by Takeda

Cambridge, UK – Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, today announces that Takeda Pharmaceutical Company Limited (Takeda) is planning to evaluate the application of recently licensed Humabodies from Crescendo for the development of novel CAR-T therapeutics.

Read more »

US Patent Office Grants the 100th Patent to Immatics Underpinning the Company’s Leading Role in the Field of Innovative Immunotherapies

Munich, Germany – Immatics, a leading company in the field of cancer immunotherapy, today announced that the United States Patent and Trademark Office has issued the 100th patent to Immatics.

Read more »

Confo Therapeutics Announces Exclusive, Worldwide License Agreement with VIB for Powerful Novel Structure Determination Technology

Ghent, Belgium – Confo Therapeutics, an emerging drug discovery company, today announces that it has entered into an agreement with VIB, a life sciences research institute in Flanders, Belgium, for an exclusive, worldwide license to VIB’s ‘Megabody’ technology.

Read more »

HOOKIPA Achieves First Research Milestone in HIV Collaboration and License Agreement with Gilead

New York, US and Vienna, Austria – HOOKIPA Pharma Inc. (“HOOKIPA”), a company developing a new class of immunotherapies targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that it has achieved its first research milestone in its collaboration and license agreement with Gilead Sciences, Inc. (“Gilead”). The agreement, which was entered into in June 2018, grants Gilead exclusive rights to HOOKIPA’s TheraT® and VaxWave® investigational arenavirus-based immunization technologies for the development of immunotherapies against hepatitis B virus (HBV) and human immunodeficiency virus (HIV).

Read more »